Form 8-K

8-K — AMARIN CORP PLC\UK

Accession: 0001193125-26-435081

Filed: 2026-10-28

Period: 2026-10-28

CIK: 0000897448

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — amrn-20261028.htm (Primary)

EX-99.1 (amrn-ex99_1.htm)

GRAPHIC (img114078973_0.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: amrn-20261028.htm · Sequence: 1

8-K

false0000897448AMARIN CORP PLC\UK00-000000000008974482026-10-282026-10-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 28, 2026

Amarin Corporation plc

(Exact name of registrant as specified in its charter)

England and Wales

0-21392

Not applicable

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

8th Floor, One Central Plaza, Dame Street,

Dublin 2, Co. Dublin, D02 K7K5, Ireland

Not applicable

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: +353 1 6699 020

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

American Depositary Shares (ADS(s)), each ADS representing the right to receive twenty (20) Ordinary Shares of Amarin Corporation plc

AMRN

Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On October 28, 2026, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three and nine months ended September 30, 2026 and 2025 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.

The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release (results of operations), dated October 28, 2026 (furnished herewith)

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 28, 2026

Amarin Corporation plc

By:

/s/ Aaron Berg

Aaron Berg

President and Chief Executive Officer

EX-99.1

Filename: amrn-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income

DUBLIN, Ireland and BRIDGEWATER, N.J., October 28, 2026 -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the third quarter ended September 30, 2026 (Q3 2026) highlighting profitable third quarter results, strong momentum in its fully partnered international business strategy and continued U.S. market share leadership.

Delivering On Our Performance Objectives

“Our results in the third quarter demonstrate the continued positive trajectory in our operational, financial and strategic transformation, underscoring the progress we are making to strengthen our business, expand the value of our VASCEPA®/VAZKEPA® (icosapent ethyl, or IPE) franchise and deliver long-term shareholder value,” said Aaron Berg, President & Chief Executive Officer. “International in-market demand grew at a double-digit pace across our partner network reflecting increased adoption by patients and prescribers, and we maintained leadership in the U.S. IPE market amid pricing pressure from generic competition.”

($ in millions)

Q4 2025

Q1 2026

Q2 2026

Q3 2026

FY 2026 Expectations

Operating Expense Reduction from Prior Year Period, Excluding Restructuring Charges

(41)%

(38)%

(22)%

Further reductions in Q4

Net Cash Provided by Operating Activities

$7.0

$6.4

$6.6

$9.2

Positive for Q4

Cash, Cash Equivalents & Short-Term Investments

$302.6

$307.8

$314.6

$323.4

~$330

Inventory

$195.9

$183.6

$164.1

$158.9

Maintain disciplined approach that aligns with demand and reflects improved contracting

Debt

Remain debt free

Global Commercial Momentum and Continued U.S. Market Leadership

•

In Europe, in-market demand for VAZKEPA increased by an estimated 68% in Q3 2026 compared with Q3 2025, reflecting strong execution and increased investment by Recordati S.p.A. (“Recordati”) under our exclusive license and supply agreement. Momentum was driven by strong performance in Spain, the UK and Italy. Growth in Europe significantly exceeded the historical European growth rates achieved by Amarin before the partnership began in Q2 2025.

•

As of September 30, 2026, VASCEPA/VAZKEPA was commercially available in 22 countries worldwide, including 11 European countries through Recordati. The Recordati agreement covers 59 countries with patent protection for VASCEPA / VAZKEPA extending through 2039 in these markets.

•

VAZKEPA was launched into the private pay market in Poland (non-reimbursed) during the month of October. Recordati is currently advancing pricing, reimbursement and market access activities to support planned

launches in additional licensed markets. These launches, when completed, are expected to increase the number of countries where VAZKEPA will be commercially available.

•

Across our global partner network, in-market demand for VASCEPA/VAZKEPA increased by an estimated 55% in Q3 2026 compared with Q3 2025.

•

In the United States, the Company’s leading share of the IPE market was 47% in Q3 2026, reinforcing the power of VASCEPA’s clinical differentiation, the trust of prescribers and patients, our proven ability to reliably supply the market and the disciplined execution of our commercial team.

•

The Company expects U.S. volumes to remain broadly stable for the remainder of FY 2026.

Financial Highlights

($ in millions)

2026

2025

% Change

9 Mos. 2026

9 Mos. 2025

% Change

Total Net Revenue

$39.6

$49.7

(20)%

$126.9

$164.4

(23)%

Operating Expenses

$18.5

$33.3

(44)%

$74.6

$141.5

(47)%

Operating Loss

$(2.4)

$(11.1)

79%

$(25.7)

$(43.8)

41%

Operating Margin %*

(6)%

(22)%

16 pts

(20)%

(27)%

7 pts

Net Loss

$0.2

$(7.7)

103%

$(17.9)

$(37.6)

52%

Net Margin

(16)%

16 pts

(14)%

(23)%

9 pts

*Operating margin is calculated as operating loss divided by total net revenue

Peter Fishman, Amarin’s Chief Financial Officer, said, “We reported our first profitable quarter in over two years, reflecting our lower expense base and the absence of charges following the completion of our previously announced $70 million cost savings initiatives. We generated positive free cash flow for the fourth consecutive quarter. Our cash balance now exceeds $323 million and our balance sheet remains debt-free.”

He continued, “We are encouraged by the in-market demand growth for VASCEPA/VAZKEPA across Europe and the rest of the world, reflecting its expanding market presence. We expect this growth to support increased partner supply purchases and related revenue over time as our partner-led sales model matures. The timing and level of product revenue will continue to reflect factors outside our direct control, including partner inventory levels, ordering patterns, as well as market access and pricing. In the U.S., we have efficiently maintained a market leading position in a highly competitive environment which continues to further strengthen our financial foundation.”

Financial Performance

Comparisons to comparable 2025 periods, unless otherwise stated

Revenues

($ in millions)

2026

2025

% Change

9 Mos. 2026

9 Mos. 2025

% Change

Product Revenue, net:

U.S.

$28.5

$40.9

(30)%

$96.4

$113.0

(15)%

Europe

$3.7

$4.1

(9)%

$14.1

$16.1

(12)%

Rest-of-World (ROW)

$4.7

$3.6

29%

$8.8

$7.1

24%

Total Product Revenue, net

$36.9

$48.6

(24)%

$119.3

$136.2

(12)%

Licensing & Royalties

$2.7

$1.1

139%

$7.6

$28.2

(73)%

Total Net Revenue

$39.6

$49.7

(20)%

$126.9

$164.4

(23)%

Total Net Revenue: U.S. sales of VASCEPA declined by 30% due largely to lower net pricing associated with changes in customer mix, driven largely by continued generic competition. Sales in Europe also decreased, which reflected launch inventory purchases in last year’s third quarter associated with the commencement of our partnered strategy; ROW sales rose 29% due to the strength and execution of our partners in their respective markets. The Company expects combined in-market demand across all its global partner markets to continue to grow on a sequential quarterly basis.

Licensing and royalty revenue in Q3 2026 rose 139% to $2.7 million and reflected increased partner sales within their respective territories.

Operating Expenses

Comparisons to comparable 2025 periods, unless otherwise stated

($ in millions)

2026

2025

% Change

9 Mos. 2026

9 Mos. 2025

% Change

COGS

$23.4

$27.5

(15)%

$78.0

$66.7

17%

SG&A

$14.3

$19.7

(27)%

$57.6

$94.9

(39)%

R&D

$4.2

$13.6

$14.4

(5)%

Restructuring

$9.4

$3.4

$32.2

(90)%

Total Operating Expenses*

$18.5

$33.3

(44)%

$74.6

$141.5

(47)%

* Total operating expenses reflect the sum of SG&A, R&D, and Restructuring expenses.

NM – Not Meaningful

COGS: Decreased 15% to $23.4 million, reflecting lower product volumes and the positive effect of more favorable API purchasing terms. We expect these API-related benefits to increase as production volumes grow, driving further cost efficiencies.

SG&A: Decreased 27% to $14.3 million, reflecting the benefits of our Global Restructuring activities completed in Q2 2026 in connection with the execution of the Recordati agreement.

R&D: Consistent with the prior year period.

A Stronger Platform for Strategic Value Creation

Mr. Berg continued, “Our financial results demonstrate the tremendous progress we have made to date, and we believe Amarin is in a stronger position than at any point in our recent history. Building on that and guided by a clear mandate to maximize shareholder value, we continue to work closely with Barclays, our exclusive financial advisor, and remain focused on working through these efforts in a timely and disciplined manner.”

Exploring Additional Therapeutic Applications for IPE

On October 25, 2026, we announced findings from the EPA for Metastasis Trial 2 (EMT2), which was an investigator-initiated Phase 3 trial sponsored and conducted by the University of Leeds and funded by Yorkshire Cancer Research and presented as a late breaker at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. Read the full press release here.

The research presented by the Chief Investigator, Professor Mark Hull, added to the scientific understanding of VAZKEPA/VASCEPA, and its potential role as an add-on therapy in improving outcomes for patients undergoing liver resection and standard of care treatment for colorectal cancer liver metastases (CRCLM). The investigational medicinal product used in EMT2 was VASCEPA in the same dosage utilized in the landmark REDUCE-IT cardiovascular outcomes study.

“Our focus remains on patients and their unmet needs, and we are energized by the potential of new possibilities for VASCEPA suggested by the outcome of this study,” said Mr. Berg. “We have long believed that we have a special molecule in IPE, and this study reinforces that conviction by pointing to potential new therapeutic applications for VASCEPA/VAZKEPA. Patent protection in Europe through 2039 provides a durable foundation to evaluate opportunities with high unmet patient needs and their potential to deliver long-term value for patients and shareholders."

Third Quarter 2026 Financial Results Conference Call and Webcast Information

Amarin will host a conference call on October 28, 2026, at 8:00 a.m. ET to discuss this information. The conference call can be accessed on the investor relations section of the Company's website at www.amarincorp.com, or via telephone by dialing 888-506-0062 within the United States, 973-528-0011 from outside the United States, and referencing conference ID 314562. A replay of the webcast will be made available until April 28, 2027. To listen to a replay of the call, dial 877-481-4010 from within the United States and 919-882-2331 from outside of the United States, and reference conference ID 54490. A replay of the call will also be available through the Company's website shortly after the call.

About Amarin

At the Heart of Amarin Corporation is a singular focus on advancing cardiovascular disease prevention worldwide. Our flagship oral prescription therapy, VASCEPA® (icosapent ethyl or IPE), is the U.S. market leader across all available IPE products and has been prescribed more than 32 million times globally. Through our independent U.S. commercial operations and global commercial partnerships, Amarin supports access to VASCEPA/VAZKEPA® across nearly 100 markets worldwide. For more information, visit www.amarincorp.com and follow Amarin on LinkedIn, X, Facebook. To be added to the Company's email list and receive news directly, please visit https://investors.amarincorp.com/email-alerts.

About VASCEPA®/VAZKEPA® (icosapent ethyl) Capsules

VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than thirty million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, China, Australia, Lebanon, the United Arab Emirates, Saudi Arabia, Qatar, Bahrain, and Kuwait. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA was granted in the United Kingdom (applying to England, Scotland, Wales, and Northern Ireland). VAZKEPA is currently approved and sold in Europe in Sweden, Finland, England/Wales, Spain, Netherlands, Scotland, Greece, Portugal, Italy, Slovenia, Romania, Denmark and Austria.

United States Indications and Limitation of Use

VASCEPA is indicated:

•

As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease.

•

As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Important Safety Information

•

VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.

•

VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.

•

It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.

•

VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin.

•

Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).

•

Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).

•

Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

•

Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.

FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.

Europe

For further information about the Summary of Product Characteristics (SmPC) for VAZKEPA® in Europe, please visit: https://www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf

Globally, prescribing information varies; refer to the individual country product label for complete information.

Use of Non-GAAP Adjusted Financial Information

Included in this press release are non-GAAP adjusted financial information as defined by U.S. Securities and Exchange Commission Regulation G. The GAAP financial measure is most directly comparable to each non-GAAP adjusted financial measure used or discussed, and a reconciliation of the differences between each non-GAAP adjusted financial measure and the comparable GAAP financial measure, is included in this press release after the condensed consolidated financial statements.

Non-GAAP adjusted net (loss) income was derived by taking GAAP net loss and adjusting it for non-cash stock-based compensation expense, restructuring expense and other one-time expenses. Management uses these non-GAAP adjusted financial measures for internal reporting and forecasting purposes, when publicly providing its business outlook, to evaluate the company’s performance and to evaluate and compensate the company’s executives. The company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP adjusted financial measures provide investors with a better understanding of the company’s historical results from its core business operations.

While management believes that these non-GAAP adjusted financial measures provide useful supplemental information to investors regarding the underlying performance of the company’s business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all the amounts associated with the company’s results of operations as determined in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future.

Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about Amarin’s outlook for achievements in 2026 and beyond; Amarin’s overall efforts to expand access and reimbursement to VASCEPA/VAZKEPA across global markets; expectations regarding potential market dynamics, payer behavior, and the competitive landscape; and the overall potential and future success of VASCEPA/VAZKEPA and Amarin that are based on the beliefs and assumptions and information currently available to Amarin. All statements other than statements of historical fact contained in this press release are forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S.

Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the fiscal year ended 2025 and subsequent quarterly reports on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.

Amarin Contact Information

Media Inquiries:

Amarin Corporation plc

PR@amarincorp.com

Investor Inquiries:

Devin Sullivan & Conor Rodriguez

The Equity Group on Behalf of Amarin

devin.sullivan.ext@amarincorp.com or conor.rodriguez.ext@amarincorp.com

Investor.relations@amarincorp.com

-Tables to Follow-

CONSOLIDATED BALANCE SHEET DATA

(U.S. GAAP)

Unaudited

September 30, 2026

December 31, 2025

(in thousands)

ASSETS

Current Assets:

Cash and cash equivalents

156,512

134,660

Restricted cash

201

Short-term investments

166,867

167,929

Accounts receivable, net

111,573

126,832

Inventory

158,850

195,910

Prepaid and other current assets

18,872

24,350

Total current assets

612,875

649,882

Operating lease right-of-use asset

6,082

6,461

Other long-term assets

3,669

1,067

Intangible asset, net

11,455

13,365

TOTAL ASSETS

634,081

670,775

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:

Accounts payable

40,429

45,355

Accrued expenses and other current liabilities

134,707

149,104

Total current liabilities

175,136

194,459

Long-Term Liabilities:

Long-term operating lease liability

5,353

6,080

Other long-term liabilities

9,180

10,955

Total liabilities

189,669

211,494

Stockholders’ Equity:

Common stock

316,272

310,184

Additional paid-in capital

1,923,521

1,923,801

Treasury stock

(70,120

)

(67,360

)

Accumulated deficit

(1,725,261

)

(1,707,344

)

Total stockholders’ equity

444,412

459,281

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

634,081

670,775

CONSOLIDATED STATEMENTS OF OPERATIONS DATA

(U.S. GAAP)

Unaudited

Three months ended September 30,

Nine months ended September 30,

(in thousands, except per share amounts)

2026

2025

2026

2025

Product revenue, net

36,890

48,558

119,293

136,210

Licensing and royalty revenue

2,660

1,112

7,600

28,217

Total revenue, net

39,550

49,670

126,893

164,427

Less: Cost of goods sold

23,369

27,462

77,954

66,728

Gross margin

16,181

22,208

48,939

97,699

Operating expenses:

Selling, general and administrative (1)

14,336

19,697

57,637

94,944

Research and development (1)

4,205

4,208

13,643

14,435

Restructuring

—

9,406

3,363

32,165

Total operating expenses

18,541

33,311

74,643

141,544

Operating loss

(2,360

)

(11,103

)

(25,704

)

(43,845

)

Interest income, net

2,371

2,783

7,845

8,277

Other income, net

304

205

1,583

372

Income (loss) from operations before taxes

315

(8,115

)

(16,276

)

(35,196

)

(Provision for) benefit from income taxes

(70

)

377

(1,641

)

(2,378

)

Net income (loss)

245

(7,738

)

(17,917

)

(37,574

)

Earnings (loss) per Ordinary Share:

Basic

0.00

(0.02

)

(0.04

)

(0.09

)

Diluted

0.00

(0.02

)

(0.04

)

(0.09

)

Weighted average Ordinary Shares:

Basic

417,766

415,531

420,178

414,607

Diluted

427,856

415,531

420,178

414,607

(1) - Excluding non-cash stock-based compensation, selling, general and administrative expenses were $13,255 and $17,938 for the three months ended September 30, 2026 and 2025, respectively, and research and development expenses were $3,910 and $3,613, respectively, for the same periods.

RECONCILIATION OF NON-GAAP NET INCOME (LOSS)

Unaudited

Three months ended September 30,

Nine months ended September 30,

(in thousands, except per share amounts)

2026

2025

2026

2025

Net income (loss) for EPS1 - GAAP

245

(7,738

)

(17,917

)

(37,574

)

Stock-based compensation expense

1,377

2,354

5,773

12,720

Restructuring

—

9,406

3,363

32,165

Litigation-Related Charges

—

9,400

—

Licensing Agreement Fees

—

5,038

ADS Ratio Change Fees

—

2,015

Net income for EPS1 - non-GAAP

1,622

4,022

619

14,364

1basic and diluted

Earnings per Ordinary Share:

Basic - non-GAAP

0.00

0.01

0.00

0.03

Diluted - non-GAAP

0.00

0.01

0.00

0.03

Earnings per ADS:

Basic - non-GAAP

0.08

0.19

0.03

0.69

Diluted - non-GAAP

0.08

0.19

0.03

0.69

Weighted average Ordinary Shares:

Basic

417,766

415,531

420,178

414,607

Diluted

427,856

416,117

431,312

415,127

GRAPHIC

Filename: img114078973_0.jpg · Sequence: 3

Binary file (26945 bytes)

Download img114078973_0.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.3

Document and Entity Information

Oct. 28, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Oct. 28, 2026

Entity Registrant Name

AMARIN CORP PLC\UK

Entity Incorporation State Country Code

Entity File Number

0-21392

Entity Tax Identification Number

00-0000000

Entity Address, Address Line One

8th Floor, One Central Plaza, Dame Street

Entity Address, Address Line Two

Dublin 2, Co.

Entity Address, City or Town

Dublin

Entity Address, Postal Zip Code

D02 K7K5

Entity Address, Country

Country Region

353

City Area Code

Local Phone Number

6699 020

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

American Depositary Shares (ADS(s)), each ADS representing the right to receive twenty (20) Ordinary Shares of Amarin Corporation plc

Trading Symbol

AMRN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Entity Central Index Key

0000897448

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Region code of country

+ References

No definition available.

+ Details

Name:

dei_CountryRegion

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration